CRISPR
is a gene-editing company that develops and commercializes gene-based medicines for the treatment of serious diseases... Read moreCRISPR
is a gene-editing company that develops and commercializes gene-based medicines for the treatment of serious diseases... Read more
News
Jun 08, 2026
Nasdaq
CRISPR: CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
Jun 03, 2026
Nasdaq
CRISPR: CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Jun 03, 2026
Zacks
CRISPR: Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
Jun 01, 2026
Nasdaq
CRISPR: CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
May 24, 2026
Yahoo
CRISPR: Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress
May 21, 2026
Seeking Alpha
CRISPR: These Are The Upcoming Catalysts For Crispr Therapeutics Stock
May 16, 2026
Nasdaq
CRISPR: CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
May 12, 2026
Seeking Alpha
CRISPR: CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
May 06, 2026
Seeking Alpha
CRISPR: Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
May 05, 2026
Owler
CRISPR Therapeutics AG: CRISPR's revenue changed from $3.51M in Dec 2025 to $4.10M in Mar 2026
CRISPR Competitors
1
2
3
4
5
6
7
8
9